Skip Navigation Links
RELIEVE-HF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure
Overall Recruitment Status: Active, currently enrolling
 
Official Title
RELIEVE-HF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure
 
Region Sponsors
California - Northern
V-Wave Ltd
 
Acronym NCT No.
RELIEVE-HF NCT03499236
 
Study Type Phase
INTERVENTIONAL
n/a
 
Purpose
The objective of the RELIEVE-HF study is to provide reasonable assurance of safety and effectiveness of the V-Wave Interatrial Shunt System by improving meaningful clinical outcomes in patients with New York Heart Association (NYHA) functional class III or ambulatory class IV heart failure (HF), irrespective of left ventricular ejection fraction, who at baseline are treated with guideline-directed drug and device therapies.
 
Detailed Description
This is a prospective, multi-center, 1:1 randomized, patient and observer blinded clinical study, with a Shunt Treatment arm and a non-implant Control arm. A total of approximately 400 patients will be randomized. Patients will be blinded during follow-up for a minimum of 12 months to a maximum of 24 months. Control patients will have the opportunity to receive a shunt once unblinded, if they provide consent and continue to meet inclusion/exclusion criteria. All implanted patients will be followed for a total of 5 years from the time of the study device implantation.
 
 
 
Inclusion Criteria
  • Both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) patients
  • NYHA Class III or ambulatory Class IV HF
  • Receiving guideline directed medical therapy (GDMT) for heart failure
  • At least one prior hospitalization for heart failure within the last year or elevated BNP level of at least 300 pg/ml or NT-proBNP level of at least 1,500 pg/ml. BNP/NT-ProBNP levels corrected for BMI
 
Exclusion Criteria
  • Systolic blood pressure = <90 or = >160 mmHg
  • Presence of Intracardiac thrombus
  • Pulmonary hypertension with PASP of = >70 mm/Hg or PVR = >4 WU
  • Significant RV dysfunction - TAPSE = <12mm or RVFAC = <25%
  • Left Ventricular End-Diastolic Diameter (LVEDD) = >8cm
  • Moderate to severe aortic or mitral stenosis
  • Stroke or TIA or DVT within the last 6 months
  • eGFR = <25 ml/min/1.73 m^2
  • Anatomical anomaly on TEE or ICE that precludes implantation of Shunt across fossa ovalis (FO) of the interatrial septum
  • Inadequate vascular access for implantation of shunt, e.g. femoral venous access for transseptal catheterization and inferior vena cava (IVC) is not patent
  • Hemodynamic heart rhythm, or respiratory instability at time of Final Exclusion Criteria
 
Keywords and/or Specific Medical Conditions
  • Heart Failure
  • Heart Diseases
  • Cardiovascular Diseases
  • Internal Medicine
  • CL7018
  • Otorhinolaryngology
 
KP Clinical Facility
  • San Francisco Medical Center
 
Clinical Area
  • Internal Medicine
  • Otolaryngology/ENT


Principal Investigator:
Alicia S Romero, MD
Contact Information:
- CTP Collaborate Team
-CTPCollaborate@kp.org
-San Francisco Medical Center


smilelady1
Do you want to receive
Email Alerts?
Sign Up Here!